{
    "root": "9714a60c-3870-4d89-923f-9206dac1e715",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Myfortic",
    "value": "20250501",
    "ingredients": [
        {
            "name": "MYCOPHENOLATE SODIUM",
            "code": "WX877SQI1G",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_67155"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "indications": {
        "text": "myfortic antimetabolite immunosuppressant indicated prophylaxis organ rejection adult patients receiving kidney transplants pediatric patients least 5 years age older least 6 months post kidney transplant . ( 1.1 ) combination cyclosporine corticosteroids . ( 1.1 ) limitations : myfortic delayed-release tablets mycophenolate mofetil tablets capsules used interchangeably . ( 1.2 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "adults : 720 mg mouth , twice daily ( 1,440 mg total daily dose ) empty stomach , 1 hour 2 hours food intake . ( 2.1 ) children : 5 years age older ( least 6 months post kidney transplant ) , 400 mg/m 2 mouth , twice daily ( maximum 720 mg twice daily ) . ( 2.2 ) crush , chew , cut tablet prior ingestion . ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "180 mg tablet : lime-green , film-coated round tablet bevelled edges imprint ( debossing ) \u201c c \u201d one side , containing 180 mg mycophenolic acid ( mpa ) mycophenolate sodium . bottles 120\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026ndc 0078-0385-66 360 mg tablet : pale orange-red , film-coated ovaloid tablet imprint ( debossing ) \u201c ct \u201d one side , containing 360 mg mycophenolic acid ( mpa ) mycophenolate sodium . bottles 120\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026ndc 0078-0386-66 storage store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect moisture . dispense tight container ( usp ) . handling keep reach sight children . myfortic tablets crushed cut order maintain integrity enteric coating [ ( 2.3 ) ] . teratogenic effects observed mycophenolate sodium [ ( 5.1 ) ] . reason myfortic tablets must crushed , avoid inhalation powder , direct contact powder , skin mucous membranes .",
    "adverseReactions": "known hypersensitivity mycophenolate sodium , mycophenolic acid ( mpa ) , mycophenolate mofetil , excipients . ( 4.1 )",
    "indications_original": "Myfortic is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. ( 1.1 ) Use in combination with cyclosporine and corticosteroids. ( 1.1 ) Limitations of Use : Myfortic delayed-release tablets and mycophenolate mofetil tablets and capsules should not be used interchangeably. ( 1.2 )",
    "contraindications_original": "In adults: 720 mg by mouth, twice daily (1,440 mg total daily dose) on an empty stomach, 1 hour before or 2 hours after food intake. ( 2.1 ) In children: 5 years of age and older (who are at least 6 months post kidney transplant), 400 mg/m 2 by mouth, twice daily (up to a maximum of 720 mg twice daily). ( 2.2 ) Do not crush, chew, or cut tablet prior to ingestion. ( 2.3 )",
    "warningsAndPrecautions_original": "180\u00a0mg tablet: Lime-green, film-coated round tablet with bevelled edges and the imprint (debossing) \u201cC\u201d on one side, containing 180\u00a0mg mycophenolic\u00a0acid (MPA) as mycophenolate sodium.\n                  Bottles of 120\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026NDC\u00a00078-0385-66\n                  360\u00a0mg tablet: Pale orange-red, film-coated ovaloid tablet with imprint (debossing) \u201cCT\u201d on one side, containing 360\u00a0mg mycophenolic\u00a0acid (MPA) as mycophenolate sodium.\n                  Bottles of 120\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026NDC\u00a00078-0386-66\n                  \n                     Storage\n                  \n                  \n                     Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture. Dispense in a tight container (USP).\n\t\t\t\t\t\t\n                  \n                     Handling\n                  \n                  Keep out of reach and sight of children. Myfortic tablets should not be crushed or cut in order to maintain the integrity of the enteric coating [see Dosage and Administration (2.3)].\n                  Teratogenic effects have been observed with mycophenolate sodium [see Warnings and Precautions (5.1)]. If for any reason the Myfortic tablets must be crushed, avoid inhalation of the powder, or direct contact of the powder, with skin or mucous membranes.",
    "adverseReactions_original": "Known hypersensitivity to mycophenolate sodium, mycophenolic acid (MPA), mycophenolate mofetil, or to any of its excipients. ( 4.1 )",
    "drug": [
        {
            "name": "Myfortic",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_67155"
        }
    ]
}